Whitepapers / Playbooks

Summary

Artificial intelligence (AI) and machine learning (ML) are transitioning from experimental pilots to foundational capabilities across the pharmaceutical value chain, spanning target identification, de novo molecule design, preclinical optimization, clinical development, pharmacovigilance, and commercial decision‑making. Building on decades of earlier computational chemistry, QSAR, and expert systems, the last ten years—especially the deep‑learning and generative‑AI era—have produced end‑to‑end platforms that can mine multimodal data, generate and prioritize novel compounds, simulate trials, and inform pricing, access, and field‑force strategies at scale. At the same time, regulators and international bodies are articulating AI‑specific ethical and governance frameworks, reframing AI from a “black box” curiosity to a regulated, high‑impact technology that must be demonstrably safe, fair, and accountable wherever it touches patients or healthcare systems.

This white paper is structured to reflect the end‑to‑end connections across the value chain and to tie high‑level trends to concrete examples. It covers how AI/ML are used in discovery, preclinical research, clinical trials commercialization, market access, and lifecycle management. It also covers cross‑cutting challenges, ethical and regulatory requirements, and practical governance models that organizations must adopt to scale AI responsibly.

Together, the paper provides a coherent narrative: AI is already changing how molecules are conceived and brought to first‑in‑human; the next decade will determine whether those early accelerations translate into sustainably higher clinical and commercial success rates under robust ethical and regulatory guardrails.